Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
ZymoGenetics
Study ID
NCT00347971
Phase
PHASE1
Status
Completed

Conditions

  • Lymphoma, Non-Hodgkin

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).

Key Dates

Start date
Jun 30, 2006
Status verified
Sep 2008
Primary completion
Apr 30, 2008
Completion
Apr 30, 2008

Study Design

Enrollment
23 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Incidence and severity of adverse events through 1 month after completing treatment [ Time Frame: During treatment and through 1 month after completing treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, Los AngelesLos AngelesCalifornia90095-

Find similar trials in Los Angeles, CA

By research site
University of California, Los Angeles· Los Angeles, CA

Related Studies